Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab ± ipilimumab as adjuvant therapy in localized renal cell carcinoma
CTR20180072Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in clear cell renal cell carcinoma (ccRCC), sponsored by Bristol Myers Squibb. Started Mar 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on CTR20180072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180072.